Kornitzer Capital Management Inc. KS Has $12.47 Million Holdings in Natera, Inc. (NASDAQ:NTRA)

Kornitzer Capital Management Inc. KS lowered its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 16.9% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 88,174 shares of the medical research company's stock after selling 17,945 shares during the period. Kornitzer Capital Management Inc. KS owned about 0.07% of Natera worth $12,469,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. LRI Investments LLC bought a new position in shares of Natera during the 4th quarter valued at $29,000. Rakuten Securities Inc. raised its holdings in shares of Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after purchasing an additional 119 shares in the last quarter. ORG Partners LLC bought a new position in shares of Natera during the 1st quarter valued at $32,000. EverSource Wealth Advisors LLC raised its holdings in shares of Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after purchasing an additional 261 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC raised its holdings in shares of Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after purchasing an additional 332 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Price Performance

Shares of Natera stock traded down $5.02 during trading on Thursday, hitting $143.38. 1,346,781 shares of the company's stock traded hands, compared to its average volume of 1,424,498. The firm's fifty day moving average price is $160.72 and its 200 day moving average price is $158.26. Natera, Inc. has a twelve month low of $92.14 and a twelve month high of $183.00. The company has a market cap of $19.58 billion, a PE ratio of -97.54 and a beta of 1.73.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The firm's revenue was up 36.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.56) EPS. As a group, equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently commented on NTRA shares. Barclays lifted their target price on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Piper Sandler lifted their target price on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. Finally, UBS Group raised their price target on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $184.63.

Insider Buying and Selling at Natera

In other Natera news, Director Gail Boxer Marcus sold 4,299 shares of the business's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total value of $719,480.64. Following the transaction, the director directly owned 8,118 shares in the company, valued at $1,358,628.48. The trade was a 34.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 6,980 shares of the business's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $150.10, for a total transaction of $1,047,698.00. Following the completion of the transaction, the chief executive officer directly owned 185,182 shares of the company's stock, valued at approximately $27,795,818.20. This represents a 3.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 53,272 shares of company stock worth $8,345,368 over the last ninety days. Corporate insiders own 7.60% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.